



The Role of PCSK9 and Its Antagonism in Human Disease

Guest Editor:

Dr. Jae Hyun Byun

Department of Medicine and
Health Sciences, McGill
University, Montréal, QC, Canada

Deadline for manuscript
submissions:

closed (31 March 2024)

Message from the Guest Editor

Since its seminal discovery in 2003, proprotein convertase subtilisin/kexin type-9 (PCSK9) has transcended from its initial role in lipid homeostasis into becoming a pivotal player in a wide range of human diseases. Initially identified for its role in regulating cholesterol levels by targeting low-density lipoprotein (LDL) receptors for degradation, PCSK9 inhibitors, including evolocumab and alirocumab, have revolutionized cardiovascular medicine as the next line of therapy in cholesterol lowering and provided new hope for patients with familial hypercholesterolemia. Moreover, cancer research has also embraced PCSK9 antagonism. Studies suggest its critical role in promoting tumor cell growth and migration, making PCSK9 a potential target for cancer therapies.

This Special Issue aims at compiling the most recent findings from PCSK9 inhibitor research and their intricate connections with human diseases that extend far beyond the realms of lipid homeostasis and atherosclerosis. Additionally, it will cover the role of PCSK9 in human cancers, neurodegenerative disorders, and the immune system's involvement in complex pathological inflammatory processes.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPlus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
X@Biomed_MDPI